IR vs PHVS: How Ingersoll Rand and Pharvaris Compare (2026)
Last updated August 2026
Short answer
IR (Ingersoll Rand) and PHVS (Pharvaris) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
IR vs PHVS: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | IR | PHVS | What it tells you |
|---|---|---|---|
| Forward P/E | 21.61 | -11.96 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.17 | -2.33 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 47% of range | 90% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.21 | 8.47 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how IR and PHVS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IR and PHVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IR and PHVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Ingersoll Rand (IR) do?
Ingersoll Rand is a global industrial-technology company built around mission-critical air, fluid, gas, and medical technologies. It operates through two segments: Industrial Technologies and Services, which sells air compressors, vacuum and blower systems, air treatment, power tools, and lifting equipment; and Precision and Science Technologies, which makes highly engineered pumps and fluid-management systems for medical, life-science, and specialty industrial uses. The company was formed in 2020 when Gardner Denver merged with the Industrial segment of the old Ingersoll-Rand, and it sells under brands such as Ingersoll Rand, Gardner Denver, Nash, and many acquired niche names. A large share of revenue comes from aftermarket parts, consumables, and service on a big installed base, which makes results steadier than a pure equipment maker. Ingersoll Rand is headquartered in Davidson, North Carolina.
What does Pharvaris (PHVS) do?
Pharvaris N.V. is a Dutch biopharmaceutical company headquartered in Leiden and listed on Nasdaq as PHVS. It works on one disease: hereditary angioedema (HAE), a rare genetic condition in which uncontrolled bradykinin signaling causes sudden, unpredictable and sometimes life-threatening swelling attacks. Its lead candidate, deucrictibant, is a small-molecule oral bradykinin B2 receptor antagonist developed in two formulations from the same molecule: an immediate-release (IR) capsule for treating attacks as they happen, and an extended-release (XR) tablet for preventing them. The company has no approved products and therefore no product revenue, so the income statement is essentially research spending funded by equity raises.
IR vs PHVS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- IR drivers: IRX operating system and margins; Disciplined bolt-on M&A.
- PHVS drivers: The deucrictibant IR filing under FDA review; The CHAPTER-3 prophylaxis readout.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Ingersoll Rand's end markets are cyclical and tied to global industrial capital spending, manufacturing activity, and specific verticals like energy and semiconductors, so downturns can slow orders and short-cycle revenue. For PHVS, the concentration risk is close to total: essentially all of the value sits in one molecule, and a complete response letter, a manufacturing or inspection issue, or a safety signal in longer follow-up would hit both indications at once.
IR or PHVS: which should you pick?
IR vs PHVS: the full fundamentals
IR. Ingersoll Rand trades at a premium to the average industrial, reflecting its high aftermarket and mission-critical mix, consistent margin expansion under IRX, and disciplined free-cash-flow-funded M&A. Q1 2026 revenue was about $1.85 billion, up roughly 8 percent, with adjusted EPS near $0.77, and management maintained full-year guidance of about 2.5 to 4.5 percent revenue growth and roughly $3.45 to $3.57 adjusted EPS. The dividend is nominal because the company prioritizes reinvestment and acquisitions over payouts.
PHVS. There is no revenue multiple to work with here, because there is no revenue: the valuation is a discounted view of what deucrictibant might sell if approved in both on-demand and prophylactic HAE. The financial statements are reported in euros while the shares trade in dollars, so the cash figure and the market cap are not directly comparable without converting. Second-quarter 2026 results were scheduled for release on August 19, 2026, after the figures above.
Headline figures (approximate, July 2026): IR shows revenue (2025) ~$7.65 billion, revenue (q1 2026) ~$1.85 billion, up ~8% YoY, 2026 revenue growth guide ~2.5% to 4.5%, 2026 adjusted eps guide ~$3.45 to $3.57; PHVS shows product revenue None. No approved products yet, cash and equivalents ~247 million euros at March 31, 2026, plus a ~$132 million follow-on closed after quarter end, r&d expense ~30.2 million euros in Q1 2026 (vs ~30.9 million a year earlier), net loss ~39.2 million euros in Q1 2026 (~0.60 euros per share).
The bottom line: IR vs PHVS
IR and PHVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IR and PHVS exposure against your real portfolio. It is not an investment adviser.
Wondering how IR or PHVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Ingersoll Rand with AI
Connect the broker you already use and ask Walnut's AI how IR fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between IR and PHVS?
+
Ingersoll Rand is a global industrial-technology company built around mission-critical air, fluid, gas, and medical technologies. Pharvaris N.V. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is IR or PHVS the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, IR or PHVS?
+
On forward P/E (as of August 2026), IR trades at 21.61x and PHVS at -11.96x, so PHVS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both IR and PHVS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of IR vs PHVS?
+
IR: Ingersoll Rand's end markets are cyclical and tied to global industrial capital spending, manufacturing activity, and specific verticals like energy and semiconductors, so downturns can slow orders and short-cycle revenue. The serial-acquisition strategy carries integration, execution, and valuation risk, and heavy reliance on M&A means growth can disappoint if the deal pipeline slows or purchase multiples rise. Foreign-exchange swings, tariffs, and supply-chain disruptions can pressure results given the global footprint. Competition across compression and flow control is intense, including from larger and lower-cost rivals. The stock trades at a premium to the average industrial, so any slowdown in margin gains or capital deployment can weigh on the multiple. PHVS: The concentration risk is close to total: essentially all of the value sits in one molecule, and a complete response letter, a manufacturing or inspection issue, or a safety signal in longer follow-up would hit both indications at once. The on-demand oral niche is no longer empty, since KalVista's sebetralstat (Ekterly) reached the market first, so deucrictibant IR would arrive as a second oral entrant needing to prove differentiation on speed, dosing or tolerability rather than on novelty alone. Prophylaxis is more crowded still, with BioCryst's oral Orladeyo, Takeda's Takhzyro, CSL's garadacimab and Ionis's donidalorsen already competing, and longer-acting and one-time gene-editing approaches in development behind them. The company is pre-revenue, burning roughly 30 million euros a quarter in research and development against a quarterly net loss near 39 million euros, so continued access to equity markets remains part of the model. Finally, at a market capitalization around 2.4 billion dollars the shares already price in a good outcome, which tends to make disappointing news asymmetric.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IR or PHVS; figures are approximate and dated (as of August 2026). Verify current data before investing.